GlobeNewswire PharmaOriginal article
SciSparc: Subsidiary NeuroThera Labs Launches Phase IIb Clinical Trial at Yale Child Study Center for First-of-its-kind Treatment for Tourette Syndrome
Phase 2SCI-110Positive
AI Analysis
Summary
SciSparc's subsidiary NeuroThera Labs announced the initiation of a Phase IIb clinical trial for SCI-110, a cannabinoid-based drug candidate for treating Tourette Syndrome in adults, at Yale Child Study Center under the direction of Dr. Michael H. Bloch.
Clinical Trial Data
Phase
Phase IIb
Outcome Details
Phase IIb clinical trial initiated at Yale Child Study Center
Importance:5/10
Sentiment:
0.60
clinical trialcannabinoidCNS disorderTourette Syndrometrial initiation
Read the original article
Published by GlobeNewswire Pharma on August 5, 2026 12:22 PM